European Journal of Clinical Pharmacology

, Volume 68, Issue 8, pp 1139–1146

N-3 fatty acid supplementation to routine statin treatment inhibits platelet function, decreases patients’ daytime blood pressure, and improves inflammatory status

Authors

    • Research & Development Unit and Nephrology Division, Assaf Harofeh Medical CenterTel- Aviv University
  • Sylvia Berman
    • Research & Development Unit and Nephrology Division, Assaf Harofeh Medical CenterTel- Aviv University
  • Ramzia Abu-Hamad
    • Research & Development Unit, Assaf Harofeh Medical CenterTel- Aviv University
  • Ahuva Golik
    • Internal Medicine Department A, Assaf Harofeh Medical CenterTel- Aviv University
  • Naomi Rahimi-Levene
    • Hematology Division, Assaf Harofeh Medical CenterTel- Aviv University
  • Shai Efrati
    • Research & Development Unit and Nephrology Division, Assaf Harofeh Medical CenterTel- Aviv University
Clinical Trial

DOI: 10.1007/s00228-012-1235-4

Cite this article as:
Doenyas-Barak, K., Berman, S., Abu-Hamad, R. et al. Eur J Clin Pharmacol (2012) 68: 1139. doi:10.1007/s00228-012-1235-4

Abstract

Objectives

N-3 fatty acids reduce the risks of cardiovascular morbidity and mortality. Administration of N-3 fatty acids to patients treated with statins may potentiate the treatment effects. We examined the operating mechanisms underlying such a combination.

Methods

Thirty-two hypercholesterolemic patients aged 30–70 years with hypercholesterolemia controlled by statins, received sequential treatments with placebo followed by 1.9 g/day of N-3 fatty acids for 23 weeks. Scheduled clinical visits included physical examination, 24-h blood pressure measurement, endothelial function evaluated by pulse wave analysis, analyses for platelet function, inflammation markers [interleukin (IL)-6, plasminogen activator inhibitor-1 (PAI-1)] and oxidative stress parameters (STAT-8-Isoprostane) were undertaken at baseline, after placebo treatment, and after 6 and 20 weeks of N-3 fatty acid intake.

Results

Platelets functions were significantly inhibited, whereas endothelial function parameters were unaltered. IL-6 significantly decreased whereas PAI-1and STAT-8-Isoprostane levels remained unaffected. Daytime blood pressure significantly decreased; however, nighttime pressure and heart rate remained unchanged. No evidence of lipid-profile improvement was observed following combined treatment with statins and N-3 fatty acids.

Conclusions

In hypercholesterolemic patients, combination of statins and N-3 fatty acid inhibits platelet aggregation, alters inflammatory status, and positively affects daytime blood pressure. Close long-term follow-up might reveal additional beneficial effects of N-3 fatty acids in this patient population.

Keywords

N-3 fatty acidStatinsPlatelets functionInflammationBlood pressure

Copyright information

© Springer-Verlag 2012